echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Good news for all patients! A list of new trends in product approval of pharmaceutical giants

    Good news for all patients! A list of new trends in product approval of pharmaceutical giants

    • Last Update: 2020-02-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical net industry] recently, multinational pharmaceutical giants have been developing new products, including Lilly new and quick acting insulin products Novartis is used for the treatment of wet AMD Beovu injections; GSK is used for joint pain relief With the approval of these products, or for the majority of patients with the gospel Lilly: insulin products have been recommended and approved by the European Union CHMP Lilly recently announced that the European Drug Administration (EMA) Committee on human pharmaceutical products (CHMP) has issued a positive review opinion, suggesting approval of the company's new meal insulin products, which can be used as part of the daily multiple injection program or delivered by insulin pump, for the treatment of adult diabetic patients It is understood that this product is a new and quick acting preparation of insulin lysine, which is currently being evaluated for adult patients with type 1 diabetes and type 2 diabetes to better manage blood glucose levels Novartis: beovu injection was approved for the treatment of wet AMD On February 19, Novartis pharmaceutical officials announced that the European Commission (EC) had approved the use of beovu (brocizumab) injection for the treatment of wet age-related macular degeneration (wet AMD) on February 17 The approval will apply to all 27 EU Member States and to the UK, Iceland, Norway and Liechtenstein It is understood that beovu is a humanized single chain antibody fragment targeting to inhibit VEGF developed by Novartis The active drug component is brolucizumab, which has a strong inhibitory effect on all subtypes of vegf-a Beovu can inhibit the growth of neovascularization, clear retinal edema and improve vision by inhibiting VEGF signal pathway Wet AMD is a chronic degenerative ophthalmopathy, which is also the main cause of visual acuity decline and blindness in people over 65 years old GSK: FDA, approved by GSK, has announced that FDA has approved Voltaren Arthritis Pain (diclofenac sodium external gel, 1%[NSAID]- arthritis pain killer) as an over-the-counter (OTC) product for adults (above 18 years old), temporarily relieving arthritic pain in hands, wrist, elbow, foot, ankle and knee It is worth mentioning that after the approval of Voltaren Arthritis Pain, it will become the first and only one in the US market to get the prescription strength and non steroidal anti inflammatory (NSAID) topical gel through OTC for treating arthritis pain Voltaren Gel is currently available in the United States only through prescription With the OTC approval of Futalin arthritis pain, it will provide nearly 30 million Americans with osteoarthritis with an external treatment option that can be obtained without a prescription Mershadong: ervebo has been approved in four African countries Mershadong recently announced that the first four African countries, including the Democratic Republic of Congo, have approved its Ebola vaccine, ervebo (rVSV? G-zebov-gp, V920, live attenuated vaccine) It is understood that ervebo was approved in the European Union on November 11, 2019, and in the United States on December 20, 2019, for active immunization of people aged 18 and over to prevent Ebola virus disease (EVD) caused by Ebola Zaire Ervebo is the world's first regulatory approved Ebola vaccine However, it should be noted that the duration of protection provided by ervebo is unknown, and the vaccine cannot protect other types of Ebola or Marburg virus.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.